University of Texas MD Anderson Cancer Center-ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2022

  1. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

    Nature Medicine, Vol. 28, Núm. 8, pp. 1640-1645

2020

  1. European Society for Medical Oncology (ESMO) 2018 Congress Twitter analysis: From ethics to results through the understanding of communication and interaction flows

    ESMO Open, Vol. 5, Núm. 1

2012

  1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246